Denosumab biosimilar (Biocon Biologics)

地舒单抗生物类似药 (Biocon Biologics)

Report date: 2026/04/22 20:01:10

Base Information

Drug NameDenosumab biosimilar (Biocon Biologics)
Drug Alias NameDenosumab BBLVevzuoEvfraxyBmab-1000
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar
Mechanisms of ActionTumor necrosis factor ligand superfamily member 11 inhibitors
TargetsTumor necrosis factor ligand superfamily member 11
Therapy Area/IndicationsBone metastasesGlucocorticoid-induced osteoporosisBone Resorption +[8] 
Global Approved IndicationsGlucocorticoid-induced osteoporosisOsteoporosis, PostmenopausalOsteoporosis +[6] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2025/06/25
Country/TerritoryCanadaUnited StatesUnited Kingdom +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesBiocon Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBiocon Biologics IncBiosimilar Collaborations Ireland LtdBiocon Biologics Ltd
Inactive CompaniesN/A
Active IndicationsBone metastasesGlucocorticoid-induced osteoporosisBone Resorption +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A